KHAN Technology Transfer Fund I (KHAN-I) is an early-stage life sciences venture fund with € 70 millions under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need.
KHAN Technology Transfer Fund I (KHAN-I) is an early-stage life sciences venture fund with € 70 millions under management. Our mission is to create value through cooperative drug development partnerships with academic innovators in Europe. KHAN-I focuses on first-in-class therapies for attractive markets with a high unmet medical need.
KHAN-I benefits from an investment of the European Investment Fund (EIF), with funding provided by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Partnership for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.
Austria Wirtschaftsservice Gesellschaft mbH (aws) is the promotional bank of the Austrian government. aws funds for KHAN-I are provided by the Austrian Federal Ministry of Labour and Economy and the Austrian National Foundation for Research, Technology and Development (NFTE).
The Max Planck Foundation is an independent, non-profit organization of private supporters of top research in the Max Planck Society.
Thyssen’sche Handelsgesellschaft (THG) is a German single-family office with roots in the Julius Thyssen family. THG follows a long-term investment approach and owns a highly diversified set of portfolio companies in different industry segments.
KHAN-I benefits from an investment of the European Investment Fund (EIF), with funding provided by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Partnership for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.
Austria Wirtschaftsservice Gesellschaft mbH (aws) is the promotional bank of the Austrian government. aws funds for KHAN-I are provided by the Austrian Federal Ministry of Labour and Economy and the Austrian National Foundation for Research, Technology and Development (NFTE).
The Max Planck Foundation is an independent, non-profit organization of private supporters of top research in the Max Planck Society.
Thyssen’sche Handelsgesellschaft (THG) is a German single-family office with roots in the Julius Thyssen family. THG follows a long-term investment approach and owns a highly diversified set of portfolio companies in different industry segments.
The Max Planck Society (MPG) and KHAN-I have set-up a strategic partnership agreement to jointly invest into the translation of promising early-stage academic projects in the field of drug discovery originating from Max Planck Institutes.
Both MPG and KHAN-I have the right to jointly co-fund such MPG projects on a 50:50 basis. Overall, MPG provides up to € 18 million for co-investments with KHAN-I.
The Max Planck Society (MPG) and KHAN-I have set-up a strategic partnership agreement to jointly invest into the translation of promising early-stage academic projects in the field of drug discovery originating from Max Planck Institutes.
Both MPG and KHAN-I have the right to jointly co-fund such MPG projects on a 50:50 basis. Overall, MPG provides up to € 18 million for co-investments with KHAN-I.
In order to close the gap in translating science into products and to help scientific discoveries to unfold their full potential, KHAN-I operates in close partnership with the Lead Discovery Center GmbH (LDC) in Dortmund and Munich. The LDC is a fully operational drug discovery incubator with an established broad academic and industrial network. It provides state-of-the art drug discovery services in accordance with industry standards. KHAN-I owns all IP rights of KHAN-financed projects.
We do not require a …
We help our investments to …
We do not require a …
We help our investments to …
The KHAN-I fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug discovery & development, academic spin-offs as well as pharma licensing and partnering.
The KHAN-I fund is managed by Khanu Management GmbH, an experienced team of professionals with proven track records in early-stage drug discovery & development, academic spin-offs as well as pharma licensing and partnering.
